Evidence map›Paper›PMID 37686007›Full record

ArticleInternational journal of molecular sciences2023

The Stabilization of S100A9 Structure by Calcium Inhibits the Formation of Amyloid Fibrils.

Ella Sanders, Rebecca Csondor, Darius Šulskis, Ieva Baronaitė, Vytautas Smirnovas, Luckshi Maheswaran, Jack Horrocks, Rory Munro, Christina Georgiadou, Istvan Horvath and 2 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Dysregulated S100A9 Expression Impairs Matrix Deposition in Chronic Wounds.International journal of molecular sciences · 2024
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 3 countries.

Ella SandersCentre for Biological Sciences, University of Southampton, Southampton SO17 1BJ, UK.
Rebecca CsondorCentre for Biological Sciences, University of Southampton, Southampton SO17 1BJ, UK.ORCID 0000-0003-1015-8656
Darius ŠulskisSector of Amyloid Research, Institute of Biotechnology, Life Sciences Centre, Vilnius University, LT-10257 Vilnius, Lithuania.ORCID 0000-0002-6925-4469
Ieva BaronaitėSector of Amyloid Research, Institute of Biotechnology, Life Sciences Centre, Vilnius University, LT-10257 Vilnius, Lithuania.ORCID 0009-0006-5515-8528
Vytautas SmirnovasSector of Amyloid Research, Institute of Biotechnology, Life Sciences Centre, Vilnius University, LT-10257 Vilnius, Lithuania.ORCID 0000-0002-1829-5455
Luckshi MaheswaranCentre for Biological Sciences, University of Southampton, Southampton SO17 1BJ, UK.
Jack HorrocksCentre for Biological Sciences, University of Southampton, Southampton SO17 1BJ, UK.
Rory MunroCentre for Biological Sciences, University of Southampton, Southampton SO17 1BJ, UK.
Christina GeorgiadouCentre for Biological Sciences, University of Southampton, Southampton SO17 1BJ, UK.ORCID 0000-0001-5331-1978
Istvan HorvathDepartment of Medical Biochemistry and Biophysics, Umeå University, SE-90187 Umeå, Sweden.ORCID 0000-0003-4262-1430
Ludmilla A Morozova-RocheDepartment of Medical Biochemistry and Biophysics, Umeå University, SE-90187 Umeå, Sweden.ORCID 0000-0001-5886-2023
Philip T F WilliamsonCentre for Biological Sciences, University of Southampton, Southampton SO17 1BJ, UK.ORCID 0000-0002-0231-8640
University of Southampton · GBVilnius University · LTUmeå University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The calcium-binding protein S100A9 is recognized as an important component of the brain neuroinflammatory response to the onset and development of neurodegenerative disease. S100A9 is intrinsically amyloidogenic and in vivo co-aggregates with amyloid-β peptide and α-synuclein in Alzheimer's and Parkinson's diseases, respectively. It is widely accepted that calcium dyshomeostasis plays an important role in the onset and development of these diseases, and studies have shown that elevated levels of calcium limit the potential for S100A9 to adopt a fibrillar structure. The exact mechanism by which calcium exerts its influence on the aggregation process remains unclear. Here we demonstrate that despite S100A9 exhibiting α-helical secondary structure in the absence of calcium, the protein exhibits significant plasticity with interconversion between different conformational states occurring on the micro- to milli-second timescale. This plasticity allows the population of conformational states that favour the onset of fibril formation. Magic-angle spinning solid-state NMR studies of the resulting S100A9 fibrils reveal that the S100A9 adopts a single structurally well-defined rigid fibrillar core surrounded by a shell of approximately 15-20 mobile residues, a structure that persists even when fibrils are produced in the presence of calcium ions. These studies highlight how the dysregulation of metal ion concentrations can influence the conformational equilibria of this important neuroinflammatory protein to influence the rate and nature of the amyloid deposits formed.

Indexed as

CalciumNeurodegenerative DiseasesAmyloidCalcium, DietaryCalgranulin BHumansNuclear Magnetic Resonance, BiomolecularAmyloidCalciumCalcium, DietaryCalgranulin BAlzheimer’s diseaseamyloidneurodegenerative diseaseParkinson’s diseaseprotein stabilityS100A9

Identifiers

PMID37686007
PMCPMC10488161
OpenAlexW4386162070

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.